Literature DB >> 31180122

Sustained imaging response and hearing preservation with low-dose bevacizumab in sporadic vestibular schwannoma.

Matthias A Karajannis1, Mari Hagiwara2, Mark Schreyer3, Sofia Haque3.   

Abstract

Entities:  

Keywords:  bevacizumab; hearing loss; vestibular schwannoma

Mesh：

Substances：

Year:  2019        PMID： 31180122      PMCID： PMC6556842          DOI： 10.1093/neuonc/noz051

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  6 in total

1.  Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort.

Authors:  Katrina A Morris; John F Golding; Claire Blesing; D Gareth Evans; Rosalie E Ferner; Karen Foweraker; Dorothy Halliday; Raj Jena; Catherine McBain; Martin G McCabe; Angela Swampillai; Nicola Warner; Shaun Wilson; Allyson Parry; Shazia K Afridi
Journal:  J Neurooncol       Date:  2016-10-28       Impact factor: 4.130

2.  Comparing costs of microsurgical resection and stereotactic radiosurgery for vestibular schwannoma.

Authors:  Zane Schnurman; John G Golfinos; David Epstein; David R Friedmann; J Thomas Roland; Douglas Kondziolka
Journal:  J Neurosurg       Date:  2018-11-09       Impact factor: 5.115

Review 3.  Management of sporadic vestibular schwannoma.

Authors:  Matthew L Carlson; Michael J Link; George B Wanna; Colin L W Driscoll
Journal:  Otolaryngol Clin North Am       Date:  2015-04-15       Impact factor: 3.346

4.  Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.

Authors:  Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Marc S Ballas; Krysten Brown; Annette O Nusbaum; Tsivia Hochman; Judith D Goldberg; Kevin M Koch; John G Golfinos; J Thomas Roland; Jeffrey C Allen
Journal:  Neuro Oncol       Date:  2012-07-27       Impact factor: 12.300

5.  Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.

Authors:  Jaishri O Blakeley; Xiaobu Ye; Dan G Duda; Chris F Halpin; Amanda L Bergner; Alona Muzikansky; Vanessa L Merker; Elizabeth R Gerstner; Laura M Fayad; Shivani Ahlawat; Michael A Jacobs; Rakesh K Jain; Christopher Zalewski; Eva Dombi; Brigitte C Widemann; Scott R Plotkin
Journal:  J Clin Oncol       Date:  2016-03-14       Impact factor: 44.544

6.  Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis.

Authors:  Ka-Loh Li; Ibrahim Djoukhadar; Xiaoping Zhu; Sha Zhao; Simon Lloyd; Martin McCabe; Catherine McBain; D Gareth Evans; Alan Jackson
Journal:  Neuro Oncol       Date:  2015-08-26       Impact factor: 12.300
  6 in total
  2 in total

Review 1.  A Critical Overview of Targeted Therapies for Vestibular Schwannoma.

Authors:  Ryota Tamura; Masahiro Toda
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

2.  Current Understanding of Hearing Loss in Sporadic Vestibular Schwannomas: A Systematic Review.

Authors:  Jinlu Gan; Yanling Zhang; Jingnan Wu; Deqiang Lei; Fangcheng Zhang; Hongyang Zhao; Lei Wang
Journal:  Front Oncol       Date:  2021-08-12       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.